MEDI Medimmune (MM)

GAITHERSBURG, Md., Jan. 31 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it will present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 6, 2007, at 1:00 p.m. eastern time. The conference is being held at the Grand Hyatt New York in New York City. MedImmune's presentation will be webcast live for investors at http://www.medimmune.com/ and available for replay for a period of 30 days following the conference. About MedImmune MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com/. This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. DATASOURCE: MedImmune, Inc. CONTACT: Investors: Peter Vozzo, +1-301-398-4358, or Media: Jamie Lacey, +1-301-398-4035, both of MedImmune, Inc. Web site: http://www.medimmune.com/

Copyright